1. Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies.
- Author
-
Abdou, Yara, Pandey, Manu, Sarma, Maithreyi, Shah, Shrunjal, Baron, Jeffrey, and Ernstoff, Marc S.
- Subjects
IMMUNE checkpoint inhibitors ,CYTOTOXIC T cells ,CANCER treatment ,PROGRAMMED cell death 1 receptors ,CELL membranes ,THERAPEUTICS - Abstract
Immune checkpoints are cell surface molecules that initiate regulatory pathways which have powerful control of CD8+ cytolytic T cell activity. Antagonistic and agonistic antibodies engaging these molecules have demonstrated profound impact on immune activation and have entered clinical use for the treatment of a variety of diseases. Over the past decade, antagonistic antibodies known as immune checkpoint inhibitors have become a new pillar of cancer treatment and have reshaped the therapeutic landscape in oncology. These agents differ in their mechanism of action and toxicity profiles compared to more traditional systemic cancer treatments such as chemo‐ and targeted therapies. This article reviews the pharmacology of this new class of agents. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF